S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3.

[1]  K. Bornfeldt,et al.  Novel insights into the role of S100A8/A9 in skin biology , 2012, Experimental dermatology.

[2]  Fiona M. Watt,et al.  Epithelial stem cells, wound healing and cancer , 2012, Nature Reviews Cancer.

[3]  F. Nestle,et al.  The multitasking organ: recent insights into skin immune function. , 2011, Immunity.

[4]  R. Gallo,et al.  Antimicrobial peptides: Old Molecules with New Ideas , 2011, The Journal of investigative dermatology.

[5]  Y. Hiroshima,et al.  Lipopolysaccharide-Mediated Induction of Calprotectin in the Submandibular and Parotid Glands of Mice , 2011, Inflammation.

[6]  S. Yuspa,et al.  Novel S100A7 (psoriasin)/S100A15 (koebnerisin) subfamily: highly homologous but distinct in regulation and function , 2011, Amino Acids.

[7]  B. Spencer‐Dene,et al.  Distinct roles for S100a8 in early embryo development and in the maternal deciduum , 2011, Developmental dynamics : an official publication of the American Association of Anatomists.

[8]  S. Yuspa,et al.  Gene from a Psoriasis Susceptibility Locus Primes the Skin for Inflammation , 2010, Science Translational Medicine.

[9]  E. Wagner,et al.  Psoriasis: what we have learned from mouse models , 2010, Nature Reviews Rheumatology.

[10]  M. Mildner,et al.  The antimicrobial heterodimer S100A8/S100A9 (calprotectin) is upregulated by bacterial flagellin in human epidermal keratinocytes. , 2010, The Journal of investigative dermatology.

[11]  A. Hayday,et al.  Epithelial decision makers: in search of the 'epimmunome' , 2010, Nature Immunology.

[12]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[13]  Michael Detmar,et al.  Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis , 2009, Proceedings of the National Academy of Sciences.

[14]  E. Wagner,et al.  TNFalpha shedding and epidermal inflammation are controlled by Jun proteins. , 2009, Genes & development.

[15]  K. Sayama,et al.  IL‐17 and IL‐22 mediate IL‐20 subfamily cytokine production in cultured keratinocytes via increased IL‐22 receptor expression , 2009, European journal of immunology.

[16]  W. B. van den Berg,et al.  Scavenger receptor class A type I/II determines matrix metalloproteinase-mediated cartilage destruction and chondrocyte death in antigen-induced arthritis. , 2009, Arthritis and rheumatism.

[17]  P. Schirmacher,et al.  S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis , 2009, Hepatology.

[18]  Frank O. Nestle,et al.  Mechanisms of Disease: Psoriasis. , 2009 .

[19]  L. Boon,et al.  Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis1 , 2009, The Journal of Immunology.

[20]  J. Carucci,et al.  Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis1 , 2008, The Journal of Immunology.

[21]  B. Nilsson,et al.  The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb). , 2008, Molecular immunology.

[22]  E. Lundberg,et al.  Toward a Confocal Subcellular Atlas of the Human Proteome*S , 2008, Molecular & Cellular Proteomics.

[23]  A. Enk,et al.  RAGE signaling sustains inflammation and promotes tumor development , 2008, The Journal of experimental medicine.

[24]  E. Wagner,et al.  Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease , 2008, Arthritis research & therapy.

[25]  John D Lambris,et al.  The role of complement in inflammatory diseases from behind the scenes into the spotlight. , 2007, The American journal of pathology.

[26]  S. Kaveri,et al.  Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action , 2007, Nature Clinical Practice Rheumatology.

[27]  James G. Krueger,et al.  Pathogenesis and therapy of psoriasis , 2007, Nature.

[28]  P. Angel,et al.  S100A8 and S100A9 in inflammation and cancer. , 2006, Biochemical pharmacology.

[29]  A. la Sala,et al.  Antibodies to Complement Receptor 3 Treat Established Inflammation in Murine Models of Colitis and a Novel Model of Psoriasiform Dermatitis , 2006, The Journal of Immunology.

[30]  T. Vogl,et al.  Biophysical characterization of S100A8 and S100A9 in the absence and presence of bivalent cations. , 2006, Biochimica et biophysica acta.

[31]  T. Vogl,et al.  Calcium-dependent tetramer formation of S100A8 and S100A9 is essential for biological activity. , 2006, Journal of molecular biology.

[32]  E. Wagner,et al.  Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins , 2005, Nature.

[33]  A. Zaidi,et al.  Distinct regulation of C3a-induced MCP-1/CCL2 and RANTES/CCL5 production in human mast cells by extracellular signal regulated kinase and PI3 kinase. , 2005, Molecular immunology.

[34]  G. Stingl,et al.  Identification and Characterization of pDC-Like Cells in Normal Mouse Skin and Melanomas Treated with Imiquimod1 , 2004, The Journal of Immunology.

[35]  M. Rasmussen,et al.  Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin , 2004 .

[36]  M. Dalakas,et al.  Intravenous immunoglobulin in autoimmune neuromuscular diseases. , 2004, JAMA.

[37]  H. Lutz,et al.  Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. , 2004, Blood.

[38]  P. Gasque,et al.  Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  W. Nacken,et al.  S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity , 2003, Microscopy research and technique.

[40]  N. Hogg,et al.  Myeloid Cell Function in MRP-14 (S100A9) Null Mice , 2003, Molecular and Cellular Biology.

[41]  W. Nacken,et al.  Loss of S100A9 (MRP14) Results in Reduced Interleukin-8-Induced CD11b Surface Expression, a Polarized Microfilament System, and Diminished Responsiveness to Chemoattractants In Vitro , 2003, Molecular and Cellular Biology.

[42]  S. Whittaker,et al.  Psoriasis: response to high‐dose intravenous immunoglobulin in three patients , 2002, The British journal of dermatology.

[43]  N. Hogg,et al.  A comparison of human S100A12 with MRP-14 (S100A9). , 2000, Biochemical and biophysical research communications.

[44]  N. Basset-Seguin,et al.  C3d,g deposits in inflammatory skin diseases: use of psoriatic skin as a model of cutaneous inflammation. , 1993, The Journal of investigative dermatology.

[45]  F. Acevedo,et al.  Complement C3 proteins in psoriasis , 1989, The British journal of dermatology.

[46]  Mark Lebwohl,et al.  Psoriasis , 1906, The Lancet.

[47]  D. Ricklin,et al.  Compstatin: a complement inhibitor on its way to clinical application. , 2008, Advances in experimental medicine and biology.

[48]  R. Miller,et al.  Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. , 2000, The Journal of investigative dermatology.

[49]  R. Wyatt,et al.  Complement phenotypes in patients with psoriasis. , 1989, Human heredity.